Ratings ABIONYX Pharma Börse Stuttgart

Equities

609 FR0012616852

Market Closed - Börse Stuttgart Other stock markets 07:04:07 17/05/2024 pm IST			5-day change	1st Jan Change
1.032 ^EUR	-5.84%		+10.15%	-42.73%

14/03	Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	CF
11/03	Abionyx: reduced net loss in 2023	CF

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ABIONYX PHARMA	-42.73%	40.89M	-
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B	B+
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B	B+
BIONTECH SE	-14.15%	22.41B	B+
ARGENX SE	-1.05%	22.28B	B
GENMAB A/S	-5.29%	19.07B	A-
WUXI APPTEC CO., LTD.	-38.29%	18B	A-
BEIGENE, LTD.	-4.16%	17.89B	B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B	C+
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes